SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $12.00.

Several brokerages have recently issued reports on SABS. Wall Street Zen raised shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 10th. Weiss Ratings raised shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SABS. IFP Advisors Inc bought a new stake in shares of SAB Biotherapeutics in the 2nd quarter valued at about $151,000. Seven Fleet Capital Management LP lifted its stake in SAB Biotherapeutics by 47.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company’s stock valued at $2,871,000 after purchasing an additional 236,077 shares during the last quarter. AWM Investment Company Inc. bought a new position in SAB Biotherapeutics during the second quarter worth about $1,462,000. Bank of New York Mellon Corp bought a new stake in SAB Biotherapeutics in the second quarter valued at approximately $421,000. Finally, DV Trading LLC bought a new stake in SAB Biotherapeutics in the first quarter valued at approximately $1,532,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.35 on Friday. The stock has a market capitalization of $304.82 million, a P/E ratio of -2.58 and a beta of 0.58. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 1 year low of $2.44 and a 1 year high of $5.15. The firm has a 50 day moving average of $3.26 and a 200-day moving average of $3.68.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -1.17 EPS for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.